Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brandon Cain

Vascular Surgery Greensboro, NC Medical Doctor

NPI 1730407040 CMS profile 1387443

2704 Henry St, Greensboro, NC 27405

Open in the dashboard

General payments

$7,428

230 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon Cain of Greensboro, NC is reported in the CMS Open Payments database as having received $7,428 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $432 13
2024 General $769 20
2023 General $1,063 27
2022 General $1,059 31
2021 General $396 26
2020 General $577 43
2019 General $3,132 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Cain
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Brandon Cain were reported at $432. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Brandon Cain Vascular Surgery median Middle half National median
2019 $3,132 $796 $226–$2,363 $163
2020 $577 $348 $118–$1,110 $114
2021 $396 $471 $158–$1,421 $132
2022 $1,059 $725 $222–$2,183 $149
2023 $1,063 $836 $257–$2,440 $160
2024 $769 $909 $252–$2,619 $164
2025 $432 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,137 77 payments
  2. Boston Scientific Corporation $1,713 56 payments
  3. Silk Road Medical, Inc. $864 14 payments
  4. Inari Medical, Inc. $514 19 payments
  5. Cook Medical LLC $395 15 payments
  6. Medtronic, Inc. $374 3 payments
  7. AngioDynamics, Inc. $275 6 payments
  8. Stryker Corporation $230 4 payments
  9. Cardiovascular Systems Inc. $189 5 payments
  10. Endologix, Inc. $148 2 payments
  11. Other $589 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,105 219 payments
  2. Travel and Lodging $1,278 10 payments
  3. Education $46 1 payment
Products named General payments · program years 2019–2025
  1. General Therapies $812 6 payments
  2. ENROUTE 0.014 Guidewire $709 6 payments
  3. ENROUTE Transcarotid Stent System $709 6 payments
  4. ENROUTE Transcarotid Neuroprotection System $709 6 payments
  5. ENHANCE Transcarotid Peripheral Access Kit $709 6 payments
  6. C3 Delivery System $559 17 payments
  7. CT THROMBECTOMY SYSTEM KIT $537 20 payments
  8. FLOWTRIEVER CATHETER, S $537 20 payments
  9. VIABAHN VBX Balloon Expandable Endoprosthesis $384 20 payments
  10. ENDURANT IIS $374 3 payments
  11. Other $4,033 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

717

Median for Vascular Surgery: 122

Drug cost

$89,728

Median for Vascular Surgery: $14,135

Branded share of claims

75%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 86 $61,131
Xarelto Rivaroxaban Brand 27 $21,507
Clopidogrel Clopidogrel Bisulfate Brand 425 $5,016
Rosuvastatin Calcium Generic 85 $793
Atorvastatin Calcium Generic 34 $668
Cilostazol Generic 49 $606
Lorazepam Generic 11 $6

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$69,244

Medicare's payments for the services billed

Medicare patients

477

Average age 75

Services billed

914

229 women, 248 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 50%
Chronic kidney disease 47%
Diabetes 43%
Heart failure 40%
COPD 29%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record